Key result
Higher MHR tertile is linked to ~25% higher 1-year mortality in critically ill CHD patients.
Why the study?
Does an elevated monocyte-to-HDL-cholesterol ratio predict increased 1-year all-cause mortality in critically ill patients with coronary heart disease?
Cohort (n=3,004)
Does an elevated monocyte-to-HDL-cholesterol ratio predict increased 1-year all-cause mortality in critically ill patients with coronary heart disease?
Answers are grounded in this paper and cite their sources.
An elevated monocyte-to-HDL-cholesterol ratio is independently associated with increased 1-year all-cause mortality in critically ill patients with coronary heart disease, suggesting its potential as a prognostic biomarker.
Objective The monocyte-to-high-density lipoprotein cholesterol ratio (MHR) integrates inflammatory burden with anti-inflammatory lipid status, yet its prognostic value for long-term outcomes in critically ill patients with coronary heart disease (CHD) remains unclear. This study aimed to evaluate the association between MHR and 1-year all-cause mortality in this high-risk population. Methods We conducted a retrospective cohort study using data from the Medical Information Mart for Intensive Care (MIMIC)-III and IV databases (2001–2019). Adult patients (≥18 years) with CHD were included, excluding those with ICU stay <24 hours or missing monocyte count/HDL-C data, yielding 3,004 patients. MHR was calculated as monocyte count (×10 9 /L) divided by HDL-C (mmol/L). The primary outcome was 1-year all-cause mortality. Kaplan-Meier analysis and log-rank tests compared survival across MHR tertiles. Restricted cubic splines assessed dose-response relationships. Multivariable Cox proportional hazards regression with progressive adjustment evaluated MHR-mortality associations. Subgroup analyses examined effect modification across predefined clinical characteristics. Results The cohort had a mean age of 73.5 years, with 65.8% males. Patients in the highest MHR tertile (T3) demonstrated greater disease severity, higher comorbidity burden, and more intensive treatment requirements. Kaplan-Meier analysis revealed significantly lower 1-year survival in T3 versus T1 (68% vs. 80%, log-rank P <0.001). Restricted cubic spline analysis showed a linear relationship (P for non-linearity=0.441). After adjustment for demographics, vital signs, comorbidities, laboratory parameters, and treatments, each 1-unit increase in MHR conferred a HR of 1.33 (95% CI: 1.18-1.51), per-SD HR = 1.10, 95% CI: 1.03-1.17. Tertile analysis demonstrated a dose-response pattern, with T3 showing HR=1.25 (95% CI: 1.04-1.51) compared with T1 ( P for trend<0.05). Subgroup analyses revealed consistent associations across most strata. Conclusions Elevated MHR is associated with increased 1-year mortality in critically ill CHD patients. As a readily available composite marker, MHR may have supplementary prognostic relevance, but its clinical utility requires prospective validation.
No takes yet. Share an insight, caveat, or question.
Li et al. (2026) conducted a cohort in Critically ill coronary heart disease (n=3,004). Highest monocyte-to-HDL-cholesterol ratio tertile (T3) vs. Lowest MHR tertile (T1) was evaluated on 1-year all-cause mortality (HR 1.25, 95% CI 1.04-1.51, p=<0.05). In critically ill patients with coronary heart disease, the highest MHR tertile was associated with increased 1-year mortality compared to the lowest tertile.
Synapse has enriched 10 related papers. Consider them for comparative context: